Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. April 2013 03:00 ET | Quelle: Pluri Inc.

Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine

HAIFA, Israel, April 18, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it is expanding its...
11. April 2013 03:00 ET | Quelle: Pluri Inc.

United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

HAIFA, Israel, April 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that following favorable...
10. April 2013 07:18 ET | Quelle: Gilat Satellite Networks Ltd.

Gilat to Showcase Field Proven Cellular Backhaul Solutions at April Events

PETAH TIKVA, Israel, April 10, 2013 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq:GILT), a worldwide leader in satellite networking technology, solutions and services, today announced that...
10. April 2013 02:00 ET | Quelle: Pluri Inc.

Pluristem Announces Scientific and Investment Conferences for April 2013

HAIFA, Israel, April 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the Company is scheduled...
02. April 2013 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease

CARMIEL, Israel, April 2, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company's phase I clinical...
02. April 2013 02:29 ET | Quelle: Bank Hapoalim

Bank Hapoalim Announces 2012 Financial Results

Net Profit totaled NIS 2,543 million Return on Equity of 10.1% Core Tier 1 Capital rose to 8.9% TEL AVIV, Israel, April 2, 2013 (GLOBE NEWSWIRE) -- Bank Hapoalim (TASE:POLI) (ADR:BKHYY),...
20. März 2013 14:13 ET | Quelle: D. Medical Industries Ltd.

D. Medical Announces Voluntary SEC Deregistration

GRANOT, Israel, March 20, 2013 (GLOBE NEWSWIRE) -- D. Medical Industries Ltd. (OTCBB:DMEDF) (TASE:DMED) ("D. Medical" or the "Company"), announced today that its Board of Directors approved the filing...
20. März 2013 08:00 ET | Quelle: Gilat Satellite Networks Ltd.

HISPASAT Expands Broadband Satellite-Based Network With Additional SkyEdge II System From Gilat

PETAH TIKVA, Israel, March 20, 2013 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq:GILT), a worldwide leader in satellite networking technology, solutions and services, today announced that...
20. März 2013 04:14 ET | Quelle: GAZIT-GLOBE LTD

Gazit-Globe Reports Year-End and Fourth Quarter 2012 Financial Results

Total Investments of NIS 5.7 Billion During 2012 FFO and FFO Per Share Grew by 32% and 23% Respectively, Same Property NOI Grew by 3.9% TEL-AVIV, Israel, March 20, 2013 (GLOBE NEWSWIRE)...
20. März 2013 03:00 ET | Quelle: Pluri Inc.

Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury

HAIFA, Israel, March 20, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today reported on the progress of its...

Vorherige Seite

Nächste Seite